Concepedia

Mark D. Pegram

MD

Statistics

Publications

131

Citations

39K

H-Index

62

Active since

1982

Affiliations

University of California, Los Angeles(Current)

Stanford University

University of Miami

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Mark D. Pegram is an author at University of California, Los Angeles specializing in oncology, medicine, and pharmacology.

Publications per year

1982–2023

131

Publications

131

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak et al. · New England Journal of Medicine · 2001 · 11.5K citations · Full text

Medicine, Oncology, Pharmacology +10

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz et al. · Journal of Clinical Oncology · 2006 · 4.5K citations · Full text

Medicine, Oncology, Pathology +11

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma, David Miles, Luca Gianni et al. · New England Journal of Medicine · 2012 · 3.8K citations · Full text

Medicine, Oncology, Pharmacology +14

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz et al. · Archives of Pathology & Laboratory Medicine · 2007 · 1.9K citations

Medicine, Oncology, Pathology +11

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Rashmi K. Murthy, Sherene Loi, Alicia Okines et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +12

1–5 of 131